The role of immunologic and viral markers in predicting clinical outcome in HIV infection

AIDS, Supplement

Volumn 10, Issue 5, 1996, Pages

  Graham, Neil M H ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

3TC; CD4 cell count; Clinical marker; Combination therapy; Viral load; Zidovudine

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; LAMIVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; DISEASE COURSE; DRUG ACTIVITY; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE COUNT; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS RESISTANCE;

EID: 0030498548     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199612005-00004     Document Type: Conference Paper

References (29)

1. Pantaleo G, Graziosi C, Demarest JF, et al.: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
2. Embretson J, Zupancic M, Ribas JL, et al.: Massive covert infection of helper T-lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362:359-362.
3. Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
4. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
5. Graham NMH, Zeger SL, Park LP, et al.: The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992, 326:1037-1042.
6. 3. 35th International Conference on Antimicrobial Agents. San Francisco, September 1995 [abstract LB-1].
7. Graham NMH, Hoover DR, Park LP, et al.: Survival in zidovudine-experienced patients: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Ann Intern Med 1996, 124:1031-1038.
8. Gazzard B and the DELTA Study Group: Further results of the European/Australian DELTA Trial. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January-February 1996 [abstract LB 5].
9. 3. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January-February 1996 [abstract LB 4].
10. Saah AJ, Mu-oz A, Kuo V, et al.: Predictors of the risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort study. Am J Epidemiol 1992, 135:1147-1155.
11. Fischl MA, Richman DD, Hansen N, et al.: The safety and efficacy of zidovudine in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double blind, placebo-controlled trial. Ann Intern Med 1990, 112:727-737.
12. Stein DS, Fish DG, Bilello J, et al.: A 24-week open-label phase 1 evaluation of the HIV protease inhibitor MK-639. AIDS 1996, 10:485-489.
13. Choi S, Lagakos SW, Schooley RT, Volberding PA: CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993, 118:674-680.
14. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4 T-lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995, 332:567-575.
15. Graham NMH, Piantadosi S, Park LP, Phair JP, Rinaldo CR, Fahey JL: CD4+ lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time. J Acquir Immune Defic Syndr 1993, 6:1258-1266.
16. Graham NMH, Park LP, Piantadosi S, et al.: Prognostic value of combined response markers among human immunodeficiency virus-infected persons: possible aid in the decision to change zidovudine monotherapy. Clin Infect Dis 1995, 20:352-362.
17. DeGruttola V, Beckett LA, Coombs RW, et al.: Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. J Infect Dis 1994, 169:713-721.
18. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
19. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
20. Mayers DL, Wagner KF, Chung RCY, et al.: Virologic response to DDI following prolonged zidovudine treatment. X International Conference on AIDS. Yokohama, August 1994 [abstract 359B].
21. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
22. D'Aquila RT, Johnson VA, Welles SL, et al.: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995, 122:401-408.
23. Japour AJ, Welles S, D'Aquila RT, et al.: Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients following long-term zidovudine treatment. J Infect Dis 1995, 171:1172-1179.
24. Fahey JL, Taylor JM, Detels R, et al.: The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990, 322:166-172.
25. Melmed RN, Taylor JM, Detels R, et al.: Serum neopterin changes in HIV infected subjects: indicator of significant pathology, CD4 T-cell changes and the development of AIDS. J Acquir Immune Defic Syndr 1989, 2:70-76.
26. Reddy MM, McKinley G, Englard A, Grieco MH: Effect of azidothymidine (AZT) on HIV p24 antigen, beta-2-microglobulin, neopterin, soluble CDB, soluble interleukin-2 receptor and tumor necrosis factor alpha levels in patients with AIDS-related complex or AIDS. Int J Immunopharmacol 1990, 12:737-741.
27. 2-microglobulin levels in mildly symptomatic HIV type 1 seropositive individuals. J Acquir Immune Defic Syndr 1992, 5:215-221.
28. Godfried MH, van der Poll T, Weverling GJ, et al.: Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus-type 1 infection. J infect Dis 1994, 169:739-745.
29. Bilello J, Stellrecht K, Drusano G, Stein DS: Soluble tumor necrosis factor-α receptor type 2 correlates with HIV RNA copy number in HIV infected patients. J Infect Dis 1996, 173:464-470.